Navigation Links
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Date:10/18/2007

r the treatment of HIV-1 infection in adults in the United States for use either as stand-alone therapy or in combination with other antiretroviral agents. ATRIPLA was approved by the U.S. Food and Drug Administration (FDA) in July 2006 and has since become the most-prescribed treatment regimen for patients starting HIV therapy in the United States.

The FDA also granted approval of an alternate tradedress of ATRIPLA for developing countries, where ATRIPLA is being made available as a white-colored tablet to distinguish it from the salmon-colored version currently available in the United States. In August 2006, Gilead and Merck established an agreement for distribution of the product in developing countries, and in March 2007, the World Health Organization added ATRIPLA to its Model List of Essential Medicines.

Important Product Safety Information About ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), Emtriva (emtricitabine), Viread (tenofovir disoproxil fumarate [DF]) and Truvada (emtricitabine/tenofovir DF) in the United States

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals.

Emtriva, Viread, Truvada and ATRIPLA are not approved for the treatment of chronic hepatitis B virus (HBV) infection and their safety and efficacy have not been established in patients co-infected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Viread or Emtriva, which are components of Truvada and ATRIPLA. In some of these patients treated with Emtriva, the exacerbations of hepatitis B were associated with liver decompensation and liver failure. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are co-infected with HIV and HBV and discontinue Truvada o
'/>"/>

SOURCE Bristol-Myers Squibb
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Malvern initiates European user group meetings for chemical imaging
7. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
8. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
9. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
10. Inspire Announces Presentations at Two European Scientific Conferences
11. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 ... research report is available in its ... and Compliance Services Industry (U.S.): Analytics, ... Forecasts to 2021, NAIC 541380 ... Testing Laboratories, Safety and ...
(Date:8/28/2014)... Mass. , Aug. 28, 2014  Decision ... system market will grow strongly through 2022 at ... percent. This will be largely supported by strong ... will increase demand for imaging procedures. The Indian ... allow more facilities to purchase or upgrade diagnostic ...
(Date:8/28/2014)... 28, 2014 Takeda Pharmaceutical Company Limited ... and submissions of data from a 10-year epidemiology ... United States (U.S.) Food and Drug ... the Japanese Ministry of Health, Labour, and Welfare ... Agency (PMDA) for pioglitazone containing medicines, including ACTOS ...
Breaking Medicine Technology:Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6Indian Diagnostic Imaging System Market Will Grow at 6 Percent Annually Through 2022 2Indian Diagnostic Imaging System Market Will Grow at 6 Percent Annually Through 2022 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6
... People recovering,from acute heart problems such as ... develop habits to control heart attack risk factors ... to researchers at,Mayo Clinic in Rochester. These managers ... programs that last,three years. With these risk factors ...
... 4 AstraZeneca (NYSE:,AZN) today announced that it ... U.S. Food and Drug Administration (FDA) for approval ... Aerosol for the long-term maintenance treatment of asthma ... SYMBICORT is currently approved,for the long-term maintenance treatment ...
Cached Medicine Technology:Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 2Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 3Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 4AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 2AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 3AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 4AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 5AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 6
(Date:8/28/2014)... Recently, iFitDress.com, the distinguished wedding dress manufacturer and ... bridesmaid dresses . Included in the new range are ... them are provided at deeply discounted prices, from 22 ... fast and reliable delivery service. All clients from around ... short time. As is commonly noted, international customers have ...
(Date:8/28/2014)... about the chance of ,overdiagnosis, through the NHS breast ... according to research published in the British Journal ... survey of around 2,200 women, Cancer Research UK scientists ... cent felt they fully understood the information given about ... cancers that would never have gone on to cause ...
(Date:8/28/2014)... Blood's Thicker Than Water is based on ... ties in the heart of the city. Raymond E. Blake ... about how disrespect caused two families to collide with each ... The Yayo Boyz and the M.O.B. Boyz clash in a ... onlookers in a silent terror. "Guerrilla," AKA "Real," runs his ...
(Date:8/28/2014)... August 28, 2014 Millennium Treatment Group recently ... is extremely large, and Millennium Treatment Group is working to ... that they need. , According to the National Survey ... 21 million Americans could have benefited from treatment for drug ... received help. This means that there is a large treatment ...
(Date:8/28/2014)... 2014 Millennium Treatment Group has noticed ... the workplace. A recent report from the National ... that drug abuse is costing employers an estimated $81 ... addicted to drugs affect their employers and the company ... the workplace, causing expensive problems for their employers, such ...
Breaking Medicine News(10 mins):Health News:New Selection of Chic Bridesmaid Dresses Available at iFitDress.com 2Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Drug Use Causes Problems in the Workplace 2
... ... business markets are finding doeBilling™ solutions can help them control their outside legal ... budgeting, and forecasting. Make smarter, faster decisions. , ... Wilmington, Delaware (PRWEB) March 25, 2010 ...
... ... care documentation for Military Health System personnel across the Department of Defense Enterprise ... Scottsdale, AZ ... workflow solutions, has been chosen to supply clinical workflow technology to the Department of ...
... Teenage ... and retreats. , ... (PRWEB) March 24, 2010 -- Centaur Arabian Farms, a bed and breakfast on 10 acres ... retreats on a smaller scale., , ,“We plan to finish the landscaping and construction soon ...
... reported to control the diarrhea that can accompany chemotherapy. ... anal or rectal cancers, the drug proved no better ... published online March 24 in the Journal of ... given concurrently, are standard treatments for anorectal cancers, which ...
... to people living with HIV in clinical settings can sharply ... now in the online edition of the journal " AIDS ... upcoming print issue. "We found the greatest and most ... interventions were delivered by medical care providers during HIV patients, ...
... The occurrence ... in patients with osteoporosis, including those treated with the drug family known as bisphosphonates, according to ... ... unusual type of fracture of the femur, or the thigh bone, is very low in patients ...
Cached Medicine News:Health News:doeLegal Penetrates New Markets With doeBilling Solution 2Health News:Carefx to Provide Clinical Workflow Solutions for Military Health System 2Health News:Centaur Arabian Farms Expands Facilities to Offer New Wedding and Event Venue in East Texas 2Health News:UCSF study finds clinic-based HIV prevention is effective in reducing risk behaviors 2Health News:Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures 2Health News:Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures 3Health News:Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures 4
... The Finnpipette BioControl multichannel ... as the single channel model. ... all seven multichannel and five ... Both pipettes have a recharge ...
... solution and best value in high performance ... and ultra lightweight design reduce hand fatigue ... long, lever tip ejector , Color coding ... tips or for greater performance use Hamilton ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
Medicine Products: